BioVaxys Receives License For Cancer Immunotherapy.

July 11, 2018

The New York Business Journal (7/10, George) reports biotechnology company BioVaxys “has entered into an exclusive, worldwide license agreement with Thomas Jefferson University for a immunotherapy technology developed to potentially treat ovarian cancer,...